At the Fifth Ovarian Cancer Consensus Conference (OCCC) of the Gynecologic Cancer InterGroup (GCIG) held in Tokyo, Japan, in November 2015, representatives of 29 co-operative research groups studying gynaecologic cancers gathered to establish international consensus on issues critical to the conduct of randomized trials. Group B, one of the four discussion groups, addressed three questions related to first-line therapies in newly diagnosed ovarian cancer patients.
